Ask AI
ProCE Banner Activity

InterACT Oncology Team Training: Integrating Bispecific Antibodies Into Patient-Centered Management of DLBCL—Enhancing the Patient–Provider Therapeutic Connection

Slideset

Downloadable slides from a live webinar on bispecific antibodies in DLBCL that equips healthcare professionals with foundational knowledge, practical approaches for patient-focused integration of key clinical findings, and actionable guidance for managing adverse events.

Released: February 11, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education, in partnership with Smart Patients, Inc.

ProCE Banner

Supporters

Supported by an educational grant from Genentech, a member of the Roche Group.

Genentech, a member of the Roche Group

Partners

Smart Patients, Inc.

ProCE Banner

Target Audience

This activity is intended for community hematology teams caring for patients with DLBCL, including medical oncologists, nurse practitioners, physician associates, pharmacists, nurses, and other healthcare professionals.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Differentiate high-risk features and unmet needs in newly diagnosed DLBCL to guide frontline treatment selection

  • Evaluate clinical trial data and guideline recommendations to effectively integrate bispecific antibodies into managing relapsed or refractory DLBCL

  • Formulate multidisciplinary strategies to identify, prevent, and manage cytokine release syndrome and related toxicities associated with bispecific antibodies

  • Incorporate patient goals and preferences into shared decision-making to optimize DLBCL treatment planning across the continuum of care